Mr. / M. Jason Hu
Association between baseline bone mineral density testing and the risk of fractures in men initiating androgen deprivation therapy: population-based study

Dr. / Dr Adam Kinnaird
Overall and clinically significant prostate cancer detection rates using micro-ultrasound-guided biopsy

Dr. / Dr J. Curtis Nickel
Major adverse cardiovascular events risk after androgen deprivation therapy initiation is higher for older patients

Dr. / Dr Jonathan Suderman
Active surveillance in men with intermediate-risk prostate cancer

Dr. / Dr Kristen McAlpine
Development of a patient decision aid to facilitate shared decision-making for men with a BRCA2 mutation considering prophylactic prostatectomy

Dr. / Dr Raj Tiwari
Variability in testosterone measurement between radioimmunoassay (RIA), chemiluminescence assay(CLIA) and liquid chromatography-tandem mass spectrometry(MS) among prostate cancer patients on androgen

Dr. / Dr Haidar Al Saffar
Patient-centred pathology reporting improves patient experience, and understanding of disease in prostate cancer care

Dr. / Dr Evan Kovac
Pathologic Gleason Grade Group 1 in Black men – implications for renaming it “not cancer” in high-risk populations

Dr. / Dr Walid Shahrour
The effect of prostate cancer center proximity on patient outcomes and treatment type selection

Mr. / M. Yazan Qaoud
Salvage partial gland ablation for recurrent prostate cancer following primary treatment with partial gland ablation: functional and oncological outcomes

Dr. / Dr Douglas Cheung
A survey of Canadian urologists and radiologists perspectives regarding the use of prostate MRI in biopsy-naïve patients

Dr. / Dr Viranda Jayalath
Statin use and survival in men receiving androgen-ablative therapies for advanced prostate cancer: a systematic review and meta-analysis of cohort studies

Emily Thain
Implementation of updated Ontario hereditary prostate cancer testing criteria at Princess Margaret Cancer Centre

Sydney L Sparanese
The evolution of the education module for men with metastatic prostate cancer (mPC) in the Prostate Cancer Supportive Care (PCSC) program before and after COVID-19 pandemic

Dr. / Dr Anne-Sophie Valiquette
Neutrophil-to-lymphocyte ratio as a predictor of response to abiraterone acetate in metastatic castration resistant prostate cancer

Dr. / Dr Mohamad Baker Berjaoui
Commonly used pharmacological agents and their effect on prostate cancer

Mrs. / Mme Raphaëlla Rosebush-Mercier
How reliable are the self-reported prostate cancer medical data? Insight from the BIOCaPPE study

Dr. / Dr Tarek Lawen
A comparison of the sarcopenic effect of Abiraterone and Enzalutamide in the treatment of metastatic prostate cancer patients

Dr. / Dr Richard Casey
A phase 1 clinical study in early stage treatment naive prostate cancer patients with ORCA -010, a replication competent oncolytic adenovirus

Mr. / M. Adree Khondker
Clinical and biochemical predictors of skeletal-related events at the time of diagnosis of castrate-resistant prostate cancer

Dr. / Dr Frédéric Pouliot
Extensive alteration of androgen precursor levels after castration in prostate cancer patients and their association with active androgen level: Importance for treatment intensification